Przejdź do zawartości
Merck

Cerebrovascular reactivity to carbon dioxide in Alzheimer's disease.

Journal of Alzheimer's disease : JAD (2013-03-13)
Lidia Glodzik, Catherine Randall, Henry Rusinek, Mony J de Leon
ABSTRAKT

There is growing evidence that cerebrovascular reactivity to carbon dioxide (CVRCO2) is impaired in Alzheimer's disease (AD). Preclinical and animal studies suggest chronic hypercontractility in brain vessels in AD. We review (a) preclinical studies of mechanisms for impaired CVRCO2 in AD; (b) clinical studies of cerebrovascular function in subjects with AD dementia, mild cognitive impairment (MCI), and normal cognition. Although results of clinical studies are inconclusive, an increasing number of reports reveal an impairment of vascular reactivity to carbon dioxide in subjects with AD, and possibly also in MCI. Thus, CVRCO2 may be an attractive means to detect an early vascular dysfunction in subjects at risk.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Sigma-Aldrich
Carbon-12C dioxide, 99.9 atom % 12C
Sigma-Aldrich
Carbon-12C dioxide, 99.99 atom % 12C